The EBMT is pleased to offer the Live Expert Debate on Controversy sessions, featuring leading specialists on HCT and CT discussing controversial clinical topics, practice-changing data, and optimal treatment sequencing. These interactive sessions contrast traditional standards with emerging strategies to guide real-world patient care.
LIVE EXPERT DEBATE
Monday, 12 April 2027
From 7:45 to 8:45 CEST
| CODE | TITLE | EXPERT | ROOM |
|---|---|---|---|
| LED-1 | Live Expert Debate on Controversy | Allo-HCT for VEXAS syndrome | C.Gurnari | DOCK 10A |
| LED-2 | Live Expert Debate on Controversy | PTCY versus ATG in myelofibrosis | N. Gaglemann & Y. Chalandon | DOCK 14 |
| LED-3 | Live Expert Debate on Controversy | How to deal with increasing costs & availability of Cellular Therapy | C. Crawley | DOCK 13 |
Tuesday, 13 April 2027
From 7:45 to 8:45 CEST
| CODE | TITLE | EXPERT | ROOM |
|---|---|---|---|
| LED-4 | Live Expert Debate on Controversy | Allogeneic SCT as preferred first line treatment for ALL adult patients with very severe aplastic anemia | F. Sicre de Fontbrune | DOCK 10A |
| LED-5 | Live Expert Debate on Controversy | Cellular therapies in the era of targeted therapies | I. Krämer & H. de Lavallade | DOCK 14 |
| LED-6 | Live Expert Debate on Controversy | Is CMV a meaningful pathogen in CAR-T patients? | R. de la Camara | DOCK 13 |